Novel antibody-peptide conjugate for combatting Neisseria gonorrhoea resistance
A novel antibody-peptide conjugate comprised of Oct-TriA1 covalently linked to an anti-N. gonorrhoeae monoclonal antibody. The linker can only be cleaved by certain species of bacteria, resulting in a highly specific therapeutic.
Applications: Novel antimicrobials
| Features | Benefits |
|---|---|
| Linker that can only be cleaved by a protease secreted by the gonococcus | Specific and selective killing of pathogenic microbes |
| Oct-TriA1 is a highly efficacious antibacterial agent | Effective killing of N. gonorrhoeae |
| Therapeutic is only released in the presence of the gonococcal IgA protease | Minimises non-selective host cell cytotoxicity that limits use of antimicrobial peptides |
| Modular, plug and play system for targeting, release, and killing of bacterial pathogens | Technology can be adapted for other pathogenic bacteria |
| Monoclonal antibody can be functionalised | Activation of immune killing to potentiate the antimicrobial |
Available For
- Co-development
- Consulting
- Licensing